Roivant starts new Phase 2b/3 trial for hair loss drug, TED study fails

April 2, 2026 5:00 AM

Roivant Sciences (NASDAQ: ROIV) announced it has begun enrolling patients in a Phase 2b/3 study of brepocitinib for lichen planopilaris ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found